You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

LODINE XL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Lodine Xl, and when can generic versions of Lodine Xl launch?

Lodine Xl is a drug marketed by Wyeth Pharms Inc and is included in one NDA.

The generic ingredient in LODINE XL is etodolac. There are twenty-three drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the etodolac profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Lodine Xl

A generic version of LODINE XL was approved as etodolac by PANGEA on April 11th, 1997.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for LODINE XL?
  • What are the global sales for LODINE XL?
  • What is Average Wholesale Price for LODINE XL?
Summary for LODINE XL
US Patents:0
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 118
Patent Applications: 4,500
DailyMed Link:LODINE XL at DailyMed
Drug patent expirations by year for LODINE XL

US Patents and Regulatory Information for LODINE XL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Pharms Inc LODINE XL etodolac TABLET, EXTENDED RELEASE;ORAL 020584-001 Oct 25, 1996 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Wyeth Pharms Inc LODINE XL etodolac TABLET, EXTENDED RELEASE;ORAL 020584-003 Jan 20, 1998 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Wyeth Pharms Inc LODINE XL etodolac TABLET, EXTENDED RELEASE;ORAL 020584-002 Oct 25, 1996 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LODINE XL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Wyeth Pharms Inc LODINE XL etodolac TABLET, EXTENDED RELEASE;ORAL 020584-001 Oct 25, 1996 ⤷  Sign Up ⤷  Sign Up
Wyeth Pharms Inc LODINE XL etodolac TABLET, EXTENDED RELEASE;ORAL 020584-002 Oct 25, 1996 ⤷  Sign Up ⤷  Sign Up
Wyeth Pharms Inc LODINE XL etodolac TABLET, EXTENDED RELEASE;ORAL 020584-003 Jan 20, 1998 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for LODINE XL

See the table below for patents covering LODINE XL around the world.

Country Patent Number Title Estimated Expiration
Finland 89005 ⤷  Sign Up
United Kingdom 2209940 SUSTAINED RELEASE ETODOLAC ⤷  Sign Up
Ireland 60311 Sustained release etodolac ⤷  Sign Up
South Korea 960009410 ⤷  Sign Up
Japan H02270820 SLOWLY RELEASABLE ETHODRUG ⤷  Sign Up
Mexico 171463 SISTEMA DE DOSIFICACION DE LIBERACION SOSTENIDA Y PROCEDIMIENTO PARA SU PREPARACION ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.